February 28, 2018 – Hadasit has signed a research collaboration agreement with Genentech, a member of the Roche Group, with over 15,000 employees working to address unmet medical needs across the United States.

Hadassah’s researcher is Prof. Itay Chowers, Chairman of the Division of Ophthalmology at Hadassah. The collaboration is based on datasets collected by Prof. Chowers’ research team. The study is to conduct a biomarker algorithm predictive abilities validation.

Genentech, headquartered in South San Francisco, Calif., is a member of the Roche Group. The company was founded in 1976 and is often considered to be the first modern biotech company. It was acquired by The Roche Group in 2009. The Genentech campus is the headquarters for Roche pharmaceutical operations in the U.S., and the Genentech Research and Early Development center operates independently within Roche.  The company’s five primary disease categories are oncology, immunology tissue growth and repair, neuroscience and infectious disease.

For more information, see: http://www.hadasit.org.il/wp-content/uploads/2018/02/Hadasit-Newsletter-Feb-2018.pdf#new_tab